Healthcare provider profile · identity verified

Scott A Addison, MD

Allopathic & Osteopathic Physicians|Family Medicine · NORTON SHORES, MI · NPI 1548236888

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Scott A Addison, MD received $37.70 in general payments during 2025 across 2 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$37.70

2 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$37.70	100.0%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$37.70	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$37.70	2	2025
Source payment records 2025-02-16 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source 2025-09-18 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	187	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	187	35

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1198	377
Lisinopril	Lisinopril	511	168
Omeprazole	Omeprazole	488	154
Levothyroxine Sodium	Levothyroxine Sodium	467	134
Amlodipine Besylate	Amlodipine Besylate	448	142
Eliquis	Apixaban	360	89
Metoprolol Succinate	Metoprolol Succinate	349	110
Losartan Potassium	Losartan Potassium	343	112
Gabapentin	Gabapentin	330	93
Rosuvastatin Calcium	Rosuvastatin Calcium	324	106
Hydrochlorothiazide	Hydrochlorothiazide	294	101
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	277	67
Pantoprazole Sodium	Pantoprazole Sodium	246	75
Tamsulosin Hcl	Tamsulosin Hcl	220	68
Potassium Chloride	Potassium Chloride	218	67
Metformin Hcl	Metformin Hcl	216	73
Jardiance	Empagliflozin	187	35
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	183	56
Furosemide	Furosemide	180	71
Allopurinol	Allopurinol	178	55
Simvastatin	Simvastatin	174	54
Carvedilol	Carvedilol	173	59
Escitalopram Oxalate	Escitalopram Oxalate	158	52
Albuterol Sulfate Hfa	Albuterol Sulfate	155	51
Bupropion Xl	Bupropion Hcl	146	50
Trazodone Hcl	Trazodone Hcl	145	49
Sertraline Hcl	Sertraline Hcl	141	46
Ozempic	Semaglutide	129	24
Metformin Hcl Er	Metformin Hcl	124	47
Atenolol	Atenolol	121	35
Montelukast Sodium	Montelukast Sodium	119	39
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	111	27
Alendronate Sodium	Alendronate Sodium	110	40
Fluoxetine Hcl	Fluoxetine Hcl	104	33
Glimepiride	Glimepiride	97	36
Metoprolol Tartrate	Metoprolol Tartrate	94	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	85	25
Propranolol Hcl Er	Propranolol Hcl	85	24
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	85	14
Fluticasone Propionate	Fluticasone Propionate	77	33
Pravastatin Sodium	Pravastatin Sodium	77	28
Trulicity	Dulaglutide	76	18
Alprazolam	Alprazolam	75	28
Finasteride	Finasteride	75	24
Clopidogrel	Clopidogrel Bisulfate	73	23
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	72	26
Duloxetine Hcl	Duloxetine Hcl	72	26
Mounjaro	Tirzepatide	69	16
Doxazosin Mesylate	Doxazosin Mesylate	68	20
Tramadol Hcl	Tramadol Hcl	67	22
Donepezil Hcl	Donepezil Hcl	66	19
Oxybutynin Chloride Er	Oxybutynin Chloride	63	16
Warfarin Sodium	Warfarin Sodium	63	18
Citalopram Hbr	Citalopram Hydrobromide	62	21
Farxiga	Dapagliflozin Propanediol	61	14
Pregabalin	Pregabalin	58	21
Buspirone Hcl	Buspirone Hcl	56	13
Rivastigmine	Rivastigmine	56	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	55	18
Lovastatin	Lovastatin	55	15
Celecoxib	Celecoxib	54	18
Torsemide	Torsemide	53	13
Spironolactone	Spironolactone	52	19
Triamcinolone Acetonide	Triamcinolone Acetonide	47	37
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	46	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	14
Ibuprofen	Ibuprofen	42	16
Klor-Con M20	Potassium Chloride	42	13
Prednisone	Prednisone	42	15
Tizanidine Hcl	Tizanidine Hcl	41	18
Ropinirole Hcl	Ropinirole Hcl	40	suppressed
Famotidine	Famotidine	39	13
Lantus	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Humalog Kwikpen U-100	Insulin Lispro	38	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	37	suppressed
Valsartan	Valsartan	36	suppressed
Paroxetine Hcl	Paroxetine Hcl	35	13
Zolpidem Tartrate	Zolpidem Tartrate	34	13
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	20
Memantine Hcl	Memantine Hcl	32	suppressed
Novolog Flexpen	Insulin Aspart	32	11
Venlafaxine Hcl Er	Venlafaxine Hcl	32	11
Xarelto	Rivaroxaban	32	suppressed
Nystatin	Nystatin	31	17
Cephalexin	Cephalexin	30	23
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	29	25
Mirtazapine	Mirtazapine	27	suppressed
Estradiol	Estradiol	26	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	25
Bupropion Hcl Sr	Bupropion Hcl	25	suppressed
Fenofibrate	Fenofibrate	23	suppressed
Meclizine Hcl	Meclizine Hcl	23	14
Valacyclovir	Valacyclovir Hcl	23	14
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Lansoprazole	Lansoprazole	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Jantoven	Warfarin Sodium	21	suppressed
Temazepam	Temazepam	21	suppressed
Lorazepam	Lorazepam	20	11
Meloxicam	Meloxicam	20	11
Azithromycin	Azithromycin	19	12
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Baclofen	Baclofen	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Naproxen	Naproxen	18	suppressed
Trimethoprim	Trimethoprim	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Nitroglycerin	Nitroglycerin	17	suppressed
Topiramate	Topiramate	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Galantamine Hbr	Galantamine Hbr	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Bumetanide	Bumetanide	14	suppressed
Carbamazepine	Carbamazepine	14	suppressed
Digoxin	Digoxin	14	suppressed
Oxcarbazepine	Oxcarbazepine	14	suppressed
Primidone	Primidone	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Methylprednisolone	Methylprednisolone	13	12
Repatha Sureclick	Evolocumab	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Levemir	Insulin Detemir	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Tiotropium Bromide	Tiotropium Bromide	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Benzonatate	Benzonatate	11	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Bydureon Bcise	Exenatide Microspheres	11	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Qulipta	Atogepant	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$37.70 · 2 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error